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Introduction
Autism Spectrum Disorder (ASD) is a developmental disorder occurring in children from
a young age and has complex causation. Individuals with ASD present with atypical socialcommunication and cognition with restricted and repetitive behaviors (American Psychiatric
Association [AAP], 2000; American Psychiatric Association [APA], 2013; Carcani-Rathwell et
al., 2006; World Health Organization [WHO], 1993). U.S. based estimates show the prevalence
of ASD published by the CDC each year has increased from 1 in 150 children to 1 in 59 from
2000 to 2014 (Baio et al., 2018; Center for Disease Control and Prevention [CDC], 2019). ASD
is early forming and is currently considered diagnostically stable at 24 months of age
(Chawarska et al., 2007; Kleinman et al., 2008; Lord et al., 2006), though the average age of
diagnosis ranges from 46 to 67 months and varies between socio-demographics (Baio et al.,
2018, Mandell et al., 2006). While variation in delays are not clear, a major factor in diagnostic
delay is the complexity of early identification process which often requires multiple clinical
appointments prior to receiving an ASD diagnosis, and much frustration amongst caretakers
(Goin-Kochel et al., 2006). Ultimately, many children with ASD who are identifiable for an early
diagnosis are not receiving a diagnosis and the benefits that come with early identification.
Early identification of children with ASD is important because it enables children to
receive resources which can help them achieve better developmental outcomes (Green et al.,
2017; National Research Council [NRC], 2001; Virues-Ortega, 2010). Research shows that
intervention has larger benefits when performed on younger children with ASD compared to
older children (Rogers, 1996). For example, studies suggest that interventions for children
utilized earlier in life have positive effects on IQ development and adaptive behavior
underscoring the need to identify earlier rather than later (Eldevik et al., 2009; Harris, 2017;
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Rogers, 1996). Research also shows that children who receive treatment before 48 months are
more likely to be placed into regular education class than those enrolled after 48 months of age
(Kasari et al., 2012). Studies that enroll high risk children for ASD to investigate outcomes have
begun to outline the benefit of the intervention groups even to the point of “reducing prodromal
ASD symptoms in the second and third years of life” (Green et al., 2017, p. 1337). The evidence
for the positive impact of earlier received interventions highlights the need for effective early
identification of children with ASD and potential for ASD.
Early Identification Process Model
Early identification involves complex multi-faceted processes informed by insights from
the public health, education, early intervention and psychometric/clinical literatures (Bricker et
al., 2013; Sheldrick 2011, 2015, 2016, 2019). Screening/monitoring and identification of
diagnosed cases are more commonly discussed in public health and epidemiology, whereas
screener development, assessment tool development, specific intervention implementation, and
diagnostic training are more commonly discussed in clinical science and psychometric research.
The process of identification roughly follows the model seen in Figure 1 (Barger et al., 2018).
The early identification process is typically initiated by monitoring (e.g. brief informal queries
about development) and screening (i.e. brief formal screeners querying about development)
wherein children with ASD and related conditions are observed during well-child visits (CDC:
“Recommendations and Guidelines”, 2019; Individuals with Disabilities Education Improvement
Act [IDEA], 2004). Screening and monitoring processes (Step A) lead to the second phase where
individuals who have been determined “at risk” by screening and/or monitoring (Step B) may be
referred for a clinical assessment (Step C; Filipek et al., 1999). In order to render an ASD
diagnosis, specialists are then required to administer and score diagnostic assessments (Step C;
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Klin & Volkmar, 1995; Klin et al., 2005). The fourth phase is the diagnosis phase (Step D),
wherein licensed clinicians match presenting symptoms to defined diagnostic information,
preferably as part of a multi-disciplinary team (Klin & Volkmar, 1995; Klin et al., 2005;
Volkmar et al., 2014a, 2014b). The final phase is treatment receipt.

Figure 1
Steps in the Process of Early Identification and Intervention of Autism Spectrum Disorders

Early Identification: Monitoring and Screening
Monitoring and screening are the first community based intentional efforts to identify any
atypical development in children (APA, 2006; Hirai et al., 2018). Monitoring refers to the
continued surveillance of children’s developmental status by health care providers that may lead
to referral for services or diagnosis for developmental delay (Barger et al., 2018; Bright Futures,
2006). Screening refers to a method of determining if a child suspected of having a disability, by
parent or health care provider, needs early intervention services (Hirai et al., 2018; National
Research Council, 2001). A U.S. study examining the prevalence of screening in early childhood
reported that in 2016 fewer than one third of children 9 through 35 months in age had received
any form of screening (Hirai et al., 2018). Between screening and monitoring, screening is the
more studied of the two (Barger et al., 2018).
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ASD screening is considered within the broader context of developmental screening
wherein a number of social and developmental milestones, including those specific to ASD, are
considered (NRC, 2001). Developmental screening and monitoring is recommended by several
federal and professional groups (Bright Futures, 2007; Office of Disease Prevention and Health
Promotion [ODPHP], 2010; Committee on Children, 2001; Johnson & Myers, 2007). ASD
specific screenings are recommended to occur around 18 to 24 months of age as this timeframe
coincides with the ability to recognize symptoms and the appropriate age of diagnosis (Lord et
al., 2006; Chawarska et al., 2007; Bright Futures, 2007).
The tools informing the screening process are referred to as screeners and are designed to
be reliable for identifying probable cases of their intended population and screening out noncases (U.S. Department of Health and Human Services [HHS], 2014). Screeners are meant to be
brief and used to indicate that an assessment is necessary and not necessarily to provide a
diagnosis (CDC, 2020; Robins, 2008). Ideally, screeners can be made more accessible by making
sure they accomodate eight-grade reading levels and are informative enough for assessment
referral (Arnold et al., 2006). Despite widespread recommendations for screening, screeners are
often underutilized by pediatricians during scheduled check-ups even though they are an
important part of early intervention systems (Hirai et al., 2018; NRC, 2001; Sand, 2005).
There exist different instruments when considering ASD identification screeners; in
particular, whether screeners are designed for use in the general population or in “at risk”
populations (Norris & Lecavalier, 2010). Both the general and at-risk populations should be
screened for developmental delays as cases are present in both levels. Level 1, population-based,
samples require screeners relevant for low-risk populations where they can be implemented in
areas like typical well-child visits to try to identify risk for atypical development (Barger et al.,
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2018; Robins, 2008; Zwaigenbaum et al., 2015). The purpose of Level 1 screeners is to increase
the number of identified children from a population sample who would otherwise continue to be
unidentified. Level 2, “high-risk”, populations are fundamentally different than Level 1
screening because these populations typically are already being served or monitored by health
care providers due to risk for developmental delays (Robins, 2008; Zwaigenbaum et al., 2015).
Early Identification: Diagnostic Assessment and Diagnosis
After the screening process, infants and children are either determined to be low risk for a
delay or carry moderate/high risk (Klin et al., 2005; Volkmar et al., 2014a). Children with
moderate or high risk continue from screening clinical assessment phases where relevant
information such as medical history and diagnostic assessments are gathered (Klin et al., 2005).
Notably, although ASD can be diagnosed by a single trained clinician, “the clinical assessment
of individuals with this disorder is most effectively conducted by an experienced
interdisciplinary team” (Klin & Volkmar, 1995, p. 5; Klin et al., 2005). Once an individual
continues from the assessment step to the diagnosis step all relevant information from the
screening and assessment phase becomes evidentiary to support or deny a diagnosis. At this
stage, diagnosis may be conducted by a single clinician or multiple clinicians who make the
ultimate clinical decision for a child’s outcome. The gold standard is to incorporate all available
resources to acquire the most accurate diagnosis which includes multi-disciplinary clinicians as
well as diagnostic scored assessments (Klin & Volkmar, 1995; Klin et al., 2005).
The tools of the assessment phase can be used to aid the clinician to determine if
individuals meet the criteria for ASD (LeCouteur et al., 2007; Klin et al., 2005; Volkmar et al.,
2014a). Two widely recommended instruments in aiding autism assessment and diagnosis are the
Autism Diagnostic Interview-Revised (ADI-R) and the Autism Diagnostic Observation Schedule

6

(ADOS) (LeCouteur et al., 2007). The ADOS is a semi-structured standardized assessment of
four modules on which an individual is observed by clinicians which is intended to “complement
information obtained from developmental tests and caregiver history” (Gotham et al., 2007). The
ADI-R is a semi-structured investigator-based interview for caregivers in reference to ICD-10
and/or DSM criteria (Lord et al., 1994). These instruments have been reported to match
characteristics in children with DSM-IV diagnosis of autism traits, however DSM-V criteria
leads to a drop off in diagnosis compared to DSM-IV when using ADOS (Foley-Nicpon et al.,
2017; LeCouteur et al., 2007; Mazefsky et al., 2013; Ventola et al., 2006). The differences in
criteria between DSM-IV criteria and DSM-V criteria is estimated to lead to fewer diagnoses of
children with PDD-NOS and Asperger’s disorder (Smith et al., 2015).
Since an ASD diagnosis is heavily reliant on the instruments used and the clinical
judgement and experience of those rendering the diagnosis (Klin et al., 2005), it is reasonable
that early identification studies take diagnostic approaches into account. These diagnostic
approaches include both the multi-disciplinary teams and highly diagnostic instruments like
ADOS/ADI-R being used in tandem to create a high quality and robust diagnosis. Figure 2
displays a framework from Barger (2018) for ranking screening accuracy studies. Two
subranges exist within this framework: clinical diagnosis exists in the range of adequate to
excellent while unacceptable to poor exists to explain research studies that measure diagnostic
accuracy without clear clinical input. The different tiers represent expected differences of
quality of diagnosis. Starting from the bottom of the framework, unacceptable indicates that a
study does not clearly indicate that the child received a formal diagnosis (e.g., assessment scores
were used to denote a diagnosis, but not clinician); very poor indicates diagnosis based on nonrecommended assessment, but does not indicate a clinician provided a diagnosis; and poor
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represents no clinical diagnosis but a positive diagnostic result from recommended assessments
such as the ADOS or ADI-R. Continuing up the framework we reach 3 levels that require
clinical diagnosis good, very good, and excellent. The difference between these tiers, all of
which use multi-informant clinical diagnoses, ranges from: good where no assessments were
referenced along with the clinical diagnosis; very good where non-widely recommended
assessments were used and along with a clinical diagnosis, and excellent where multi-informant
clinical diagnosis method is used in conjunction with widely recommended assessments. Single
clinician diagnosis can only be considered good if it is accompanied by an assessment that is not
widely recommended or very good if it is informed by a widely recommended screener. The
tiering aims to lay out the difference in quality and why studies should seek to achieve for
excellent reference standard. This framework is a proposed model and the tiering is based on
expert reasoning.

Figure 2
Framework for Sorting Screening Accuracy Studies
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Diagnostic Accuracy and Meta-analysis of Diagnostic Accuracy for Screeners

ASD screeners and assessments seek to correctly classify individuals with or without a
condition (Robins 2008). Following the intended purpose, the best measure of a screener and
assessment is to determine their ability to correctly predict a particular clinical outcome.
Diagnostic accuracy is the measure of a test’s ability to correctly identify when a condition is
present or not in an individual (Gatsonis & Paliwal, 2006). Diagnostic accuracy metrics indicate
the degree to which tools correctly classify people into cases and non-cases.
A variety of diagnostic accuracy metrics can be developed using the confusion matrix
seen in Figure 3. Understanding the multi-faceted aspects of accuracy can be aided by filling out
a confusion matrix like the one shown in Figure 3. Individuals who are screened fall into 1 of 4
categories based on their screening outcome (positive or negative) and their true condition status.
The ideal test would correctly show a positive result for all individuals with the condition and a
negative result for all individuals without the condition. This describes true positives (TP) which
are positive screens for those with the condition and true negatives (TN) which are negative
screens for those without the condition respectively. The other two classifications are individuals
who screen positive but do not truly have the condition (i.e., false positives; FP), and negative
screens who truly do have the condition, false negatives (FN).
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Figure 3
Confusion Matrix Accuracy Metrics

This row represents
all individuals who
are indicated to have
the condition.
This row represents
all individuals who
are indicated to not
have the condition.

True Positive (TP)
False Negative (FN)

False Positive (FP)
True Negative (TN)

Sensitivity =
TP/TP+FN

Specificity =
TN/FP+TN

Positive Predictive
Value = TP/TP+FP

Negative Predictive
Value = TN/FN+TN

This column
This column
represents all
represents all
individuals truly with individuals truly
the condition
without the condition
The most common measurements of accuracy are sensitivity and specificity, respectively
the ability to correctly determine those with the condition among those who truly have the
condition and the ability to determine those without the condition among those who truly do not
have the condition (Rothman, 2012). Other metrics for determining accuracy include the positive
predictive value (PPV) and the negative predictive value (NPV). The PPV finds among the
number of individuals referred, how many were accurately identified and met criteria to receive
such referral for a diagnosis, while the NPV does the opposite in that it determines among
individuals not referred how many correctly needed no referral. Sensitivity, specificity, PPV, and
NPV can be combined to get metrics that represent the diagnostic ability of the test overall such
as the positive likelihood ratio (LR+), the negative likelihood ratio (LR), and the Diagnostic
Odds Ratio (DOR). The positive likelihood ratio (LR+) divides sensitivity by 1-specificity and
the negative likelihood ratio (LR-) is measured using the reciprocal of LR+. The DOR is a ratio
of the (LR+) and the (LR-). The usefulness of these tests are their interpretation which for LR+
is: the likelihood of a positive test result in a person with a disease is more (or less, in a poorly
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designed test) likely in a person with the condition than a person without the condition.
Similarly, the LR- shows the opposite result: the likelihood of a negative test in a person without
the condition is more (or less) likely in a person without the condition than a person with the
condition. Finally, DOR indicates the odds of a person with a condition being correctly classified
when taking a test.
Systematic reviews and meta-analyses provide “a transparent and replicable method for
summarizing the literature” (Pigott 2012, p. 1). A systematic review is a structured review of
published literature to bring together all relevant studies (Uman, 2011; Siddaway et al., 2019). A
meta-analysis assesses studies collected from a systematic review quantitatively or qualitatively
and their quality and findings are reported (Armstrong, 2011; Siddaway et al., 2019; Grant &
Booth, 2009). The extraction of effect sizes from a systematic review may be combined and
synthesized into a meta-analysis (Walker et al., 2008). These reproducible studies and combined
effect estimates provide ways to assemble common studies to drive research and policy forward
(Walker et al., 2008).
The best method for screener comparison is a review of the published literature to
determine the screener with the highest diagnostic accuracy (Gatsonis & Paliwal, 2006). When
performing a quantitative review such as a meta-analysis, fixed effects or random effects will be
used. A fixed effects model assumes that there is a true effect size that studies are estimating;
these models may be used when a meta-analysis combines estimates of closely related studies
(Borenstein, 2009; Pigott and Polanin, 2020). The corollary to fixed effects is random effects
where an effect size is “similar but not identical across studies” (Borenstein et al., 2009, p. 69).
When there is more expected variability between studies a random effects model may be better
to use; for example, variability may result from differences in study settings or sampling
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procedures (Borenstein et al. 2009, p. 69). Random effects are recommended for use in most
meta-analyses (Pigott & Polanin, 2020). When combining the previous topics of meta-analysis,
diagnostic accuracy, and modeling techniques there are important choices to be made.
While the choice to utilize random or fixed effects modeling must be made prior to
running a model, the choice of how to analyze your results (univariate versus multivariate) can
be made after carefully reviewing the studies. Starting with the fewest variables, the univariate
approach is conceptually the simplest approach only using one variable to describe an outcome.
This type of approach can be useful in areas where a controlled system is possible. For example,
traditional physics and chemistry experiments studying the effect on pressure as temperature
(one variable) increases. This approach’s strength is that you can make direct assertions about
the relationship between the dependent and independent variable. The weaknesses are that the
simplicity of this approach cannot adequately address the complexity of studies that cannot
control all variables except the ones of interest.
The multivariate approach is similar to the univariate approach, but instead of one
variable, more than one variable is used to analyze an outcome or set of data. By increasing the
number of variables considered, analyses can more accurately reflect the multiple factors
impacting an outcome, thus more closely reflect a complex reality. However, this has the
potential for negative consequences and predictors for a multivariate model should be chosen
carefully. If confounded variables are included in a multivariate model misleading results can
occur. That said, the benefits of multivariate analysis over univariate cannot be understated as
multivariate approaches can more robustly describe complex relationships, a noted weakness of
the univariate approach (Jackson et al., 2010).
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According to Walter and Jadad (1999) meta-analysts have historically employed
univariate approaches by analyzing sensitivity or specificity independently, but univariate
approaches do not account for their non-independent negative correlations; multivariate
approaches do account for these correlations. Two approaches have been proposed to address
univariate limitations: the hierarchical receiver operating curve (HSROC) and the Reitsma
(Harbord & Whiting, 2009). The HSROC is a Bayesian approach that accounts for the
correlations between sensitivity and specificity (Rutter & Gatsonis, 2001). The Reitsma random
effects model allows the sensitivity and specificity to be modeled simultaneously. Both
approaches can be visualized with graphs displaying sensitivity by 1 – specificity (i.e., FPR).
Due to their addressing the fundamental limitation of correlated variables and imperfect
visualizations of traditional univariate analyses, these multivariate approaches are strongly
recommended (Jackson et al., 2010; Reitsma et al., 2005).
Modified Checklist for Autism in Toddlers
As mentioned above there are multiple screeners for ASD; however, few if any are as
widely researched as the Modified-Checklist for Autism in Toddlers (M-CHAT) (McPheeters et
al., 2016). The M-CHAT is a population level screener that was developed at Georgia State
University by Diana Robins PhD. The M-CHAT’s seminal study was published in 2001 and
since has been suggested for use as a population-based tool (Zwaigenbaum et al., 2015; Robins
et al., 2001, 2014). The M-CHAT was developed for identifying ASD in population samples and
uses questions relevant to infant and toddler development to identify red flags consistent with
ASD indicators. The M-CHAT was revised from its initial 23 questions to 20 questions in the
population-based version. A second, follow-up phase was added to confirm the results of the
first phase (Robins et al., 2014). The original M-CHAT has been translated into 69 different
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languages as of 2016, adjusted culturally, and validated home and abroad (Brennan et al., 2016;
Robins et al., 2001, 2014). A core strength of this screener is that the M-CHAT is free to access
online (in English and Spanish) and provides an instant feedback score for curious parents
(Robins et al., 2014). The psychometrics of the M-CHAT are reported to be .911 and .955 for
sensitivity and specificity for the initial screening stage without follow-up. With follow up the
sensitivity decreases to .854 and specificity increases to .993 (Robins et al., 2014).
To date, there have been two systematic reviews and meta-analysis of diagnostic
accuracy conducted on autism screeners (Yuen et al., 2018; Sanchez-Garcia et al., 2019). Yuen
(2018) reviews the M-CHAT critically concluding there is a lack of evidence for use on children
18 to 24 months of age and high risk children screened with the M-CHAT have a pooled
sensitivity of 0.83 and pooled specificity of 0.51. Sanchez-Garcia (2019) includes the M-CHAT
in their conclusion that population based screeners are effective for low risk children under the
age of 3. Sanchez-Garcia looked at 9 total screeners and found a pooled sensitivity of 0.72 and
pooled specificity of 0.98 across multiple screeners. These studies somewhat complemented one
another while Yuen called for more evidence for a specific population, Sanchez-Garcia provided
broad evidence of screener usage on that population, but not any particular screener.
The methods of these studies showed strengths in similar and different ways. Yuen’s
study provided insights by reviewing the grey literature and extracting sample characteristics
from the studies. Sanchez-Garcia provided a thorough review when it evaluated its study sample
for publication bias and performed a subgroup of analysis. Both studies used a Bayesian
approach to their meta-analysis which is a strong method of analysis for this body of work.
Despite a number of strengths, the studies by Yuen and Sanchez-Garcia have a number of
weaknesses. Common weaknesses between the studies include both their data sets suffered from
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data heterogeneity, indicating substantial between-study differences. Further, Sanchez-Garcia
missed a population-based study by Magan-Maganto et al. (2018) which matched their study
criteria. Yuen did not include some large studies such as Stenberg et al. (2014) that includes a
large low-risk sample of children screened by the M-CHAT. While no study is without
weaknesses, it is important to consider how these could have impacted their results; by leaving
out studies that matched their respective criteria, these analyses did not consider all available
information.
While there are reviews analyzing the true diagnostic ability of the M-CHAT, to our
knowledge there is no study investigating the impact of reference standard categories on
accuracy metrics. This study proposes to categorically analyze studies that screen and diagnose
children with autism using the Barger reference standard framework. This study seeks to answer
if there is a relationship between reference standard category and reported screening accuracy.
Our specific hypothesis is that there is an inverse relationship between screening accuracy and
reference standard category – in that Multi-Clinician reference standard tier will report the
lowest diagnostic accuracy and Other will report the highest.
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Methods
The structure of this systematic review was based on the “Preferred Reporting Items for
Systematic Reviews and Meta-Analysis” (PRISMA) (Moher, 2009).
Study Criteria
The papers selected for this study contained information to determine diagnostic accuracy
for unique ASD screenings using the M-CHAT and with diagnosis information using a clear
reference standard in both population based and high-risk samples. A requirement of these
studies is that the study is in English and TP, TN, FP, FN must be made available and clear in the
study, either in a flowchart or clearly described within the study. For studies whose population
samples were identical, only one study was included where the population size was the largest; if
studies were the same size the original study results was given preference.
Search Criteria
Three searches were performed for complete coverage of the timeline April 2001 to
December 31, 2019 the initial on August 2nd, 2019, a prospective search on October 17, 2019 and
a final review search on February 1, 2020. The search terms for this study were “Modified
checklist for autism in toddlers” OR MCHAT OR M-CHAT. The initial and final search used
Web of Science, EBSCO, and ProQuest. In EBSCO the following were searched: Academic
search complete, Alt health watch, Child Development and Adolescent Studies, CINAHL Plus
with full text, consumer health complete, Education source, ERIC, family and society studies
worldwide, Fuente academia premier, Health source nursing academic edition, medline, medline
with full text, mental measurements yearbook, professional development collection, psych
articles, psychology and behavioral sciences collection, psychinfo, psychtests, and social work
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abstracts; ProQuest: dissertations and thesis at GSU, ProQuest central, arts and humanities, New
Zealand, biological science, consumer health database, continental Europe, east Europe, central
Europe, education database, health and medical collection, India, Latin American, Iberian,
middle east and African, nursing and allied health, public health database, publicly available
science, social science, UK and Ireland, ProQuest dissertation and thesis, social science
premium, and education. All articles starting from April 2001 were reviewed for relevance in all
countries, in English. The ancestral search included a traditional bibliography search of articles
ultimately deemed to fit inclusion criteria. A prospective search was also performed on all
articles deemed to fit inclusion criteria via identifying relevant articles using the “cited by”
feature of Google Scholar.
The following describes the process for data abstraction of the initial, ancestral and
prospective searches. After collecting the titles and abstracts in the three searches the collected
studies underwent a title/abstract review for M-CHAT screening studies. Studies were screened
green to be included, yellow to be reviewed a second time and red to be screened out. To check
on this initial screen-out process, 26 titles and abstracts were randomly selected and coded by an
independent reviewer - good agreement was found (K = 0.77). The process then follow that
pdfs from yellow and green highlighted studies had a full text review performed for the
inclusion/exclusion criteria, the studies were organized in keep remove computer files for quality
control.
Inclusion Criteria
Studies were included if they fit the following criteria: they included M-CHAT data, they
were in English, their TP, TN, FP, and FN data was included, and had at least 10 participants.
The characteristics of these studies were independently reviewed by two separate researchers in

17

order to verify their qualities and assure that all studies that match inclusion criteria are included.
Search terms and date information was preserved through the search engine account features
using the “save search” tool. Disagreements between study qualities were resolved by a thirdparty researcher blind to either initial party’s decision and the third party decision served as
tiebreaker.
Methodologic Quality
These studies entered an assessment known as Quality Assessment of Diagnostic
Accuracy Studies-2 (QUADAS-2) which assesses the quality of the study based on potential
sources of bias in diagnostic accuracy studies. Using appendix F questions of the QUADAS-2
the domains of patient selection, interpretive bias, criterion assessment, and Domain 4: Flow and
Timing are reported for low, high, or unclear amount of bias. A “low” bias score was determined
for all domains where all questions receive a “yes” score and a “high” bias score was determined
for all domains where one or more questions receive a “no” or “unclear” bias score. The process
followed this method: All information of the QUADAS-2 appendix F was coded by myself for
all studies included in the sample set, this file was preserved for quality control. The next round
was conducted by Dr. Barger where a randomized sample of 10 studies were selected and coded,
this file was preserved for quality control. The preserved files between myself and Dr. Barger
were compared for any discrepancies between individual QUADAS-2 domain items that did not
meet 100% agreement. QUADAS-2 domain items that did not meet 100% agreement resulted in
a focused review of all 24 studies for the particular domain items in that were not in agreement.
For QUADAS-2 sections about appropriate interval between index test and reference standard
the reviewers determined that any amount of time passed 1 year for positive screens was not
appropriate and would be marked with the high bias option. Any review questions asked that
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were not directly answered by the study in clear terms was marked unclear. During the
QUADAS-2 review only the methods and results sections of included studies were reviewed for
relevant material to answer the QUADAS-2 domain items.
Reporting
The information used for calculating diagnostic accuracy was collected from the selected studies.
The information of TP, TN, FP, and FN, the screening level, and reference standard from the
original studies was directly transcribed and recorded for data analysis. As seen below in Figure
4, the scale used in Barger et al. (2018), was adapted for this study and reference standard rank
was recorded where each study matched the reference standard grouping. The original
framework mixed multi-clinician and single-clinician criteria in the Excellent, Good and Very
Good rankings. This adapted framework distinguishes multi and single from one another placing
any multi-clinician criteria above that of any single-clinician criteria.
Starting from the bottom of the framework, unacceptable, very poor, and poor have not
been changed from the original. Continuing up the framework have been changed good, very
good, and excellent. The difference between these tiers, are that multi-clinician diagnosis is now
only in excellent and good while single-clinician now only exists in a new category Adequate.
Specifically the categories are: good where single clinician diagnosis was used in conjunction
with or without recommended assessments; very good where multi-clinician diagnosis was
performed with non-widely recommended assessments or no assessments; and excellent where
multi-informant clinical diagnosis method is used in conjunction with widely recommended
assessments.
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Figure 4
Redesigned Framework for Categorical Assessment of Reference Standards

Study Variables
M-CHAT. The primary outcome variables included diagnostic accuracy outcomes that
could be derived from confusion matrices. The M-CHAT has an initial screening phase and a
follow up phase as well as two methods for determining positive criteria. The data for the initial
phase and follow-up stages were combined in studies where it was necessary, creating only 1
data set per M-CHAT screening sample. To do this, data was assessed from flow charts to
accurately report the TP, TN, FP, and FN of the final results and not any one stage specifically.
The data reported by the study was transcribed for data analysis. The complete original 23
question M-CHAT can be found in Appendix C.
Other variables abstracted included: Author, study year, M-CHAT version (original or
revised), study country, initial screen or follow up, reported screen cut-off, tested positive, tested
negative, loss to follow up, TP, TN, FP, FN, number with condition, number without condition,
total N, study reported sensitivity, study reported specificity, study reported PPV, study reported

20

NPV, study reported LR+, diagnostic system, diagnostic assessment tool used, diagnosis
determined by, publication style, study level, and QUADAS-2 criteria. Diagnostic system
categories included DSM-IV, DSM-V, ICD-9, ICD-10. Diagnostic assessment tools included
ADOS, ADI-R, Social Communication Questionnaire (SCQ), Vineland Adaptive Behavior Scale
(VABS), Childhood Autism Rating Scale (CARS), Bayley Scales of Infant Development
(BSID), and Parents’ Evaluation of Developmental Status (PEDS). Determination of diagnosis
was noted as multiple clinicians, a single clinician, ADOS or ADI-R cut-off, other screener cutoff, or unclearly reported. Study levels were reported as population based or high-risk. Data on
diagnostic measure and diagnostic determination were combined to develop proxy variables
measuring Barger et al.’s (2018) reference rating metric. Two independent raters coded 9
randomly selected studies and had perfect reliability on Study Year (K = 1.0), good agreement on
Diagnostic System (K = .75), Moderate to Perfect agreement on Diagnostic Assessment tools
(Krange = .41-1.0), Moderate agreement for multiple/single clinician (K = .50), and Substantial
agreement for population/high-risk categories (K = .94).
Analysis
Using the Meta-Analysis of Diagnostic Accuracy (MADA) package in R, the diagnostic
accuracy metrics of sensitivity, specificity, positive predictive value (PPV), negative predictive
value (NPV), and Diagnostic Odds Ratio (DOR) were assessed using the data collected from the
original studies. Bivariate Reitsma models were selected for this analysis which is a random
effects model and was specified in the MADA package by specifying the Reitsma function. For
reference standard analysis two groups were made, a combination of the multi-clinician groups
of excellent and good, referred to as Multi-Clinician, and a combination of adequate, poor, and
unacceptable, referred to as Other. Results were recorded and reported using Tables 2-7 and
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Figures 4-15 below. The relatively small universe of available studies resulted in the decision to
use α = 0.10 to indicate meaningful statistical results.

Results
Qualitative Review
As described in Figure 5 the database search yielded 2,169 studies and the ancestral
search yielded 1,462 studies. 3,422 studies were either duplicates or were excluded through the
title and abstract search and 209 studies were accessed for their full text qualities. 22 studies
were finally included in the analysis. Two publications reported data on multiple independent
samples within each manuscript (each had two independent samples). Thus, we report analyses
on 24 data-sets across 22 total studies. Of these 24 sample sets 15/24 (62%) are population based
and 9/24 (38%) are clinical/high risk samples.
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Figure 5
PRISMA Flowchart of Study Selection

Exclusion

-

Study does not use the M-CHAT

-

Study does not include data on true
positives/true negatives

-

Study includes data on accuracy
metrics but the numbers are not
consistent across the published study

-

Study is not in English

The characteristics of the included studies are presented in Table 1. All identified studies
were published between 2008 and 2019, and were conducted across 14 countries. The wide range
of diagnostic measures used are also available for analysis. The ADI-R and ADOS are the most
commonly reported 13/22 (59%) studies that use them because they are widely recommended
instruments. There are 24 sample sets of which 15/24 (62%) are population based and 9/24
(38%) are clinical/high risk samples. There are 4 Excellent, 3 Good, 11 Adequate, 2 Poor, and 2
Unacceptable studies ranked by reference standard criteria.

Table 1
Summary of Included Study Characteristics

Diagnostic Measure

Diagnosis

Rank Based on
Figure 4

Population Based/General Population

ADOS, VABS, PEP-R

Single Clinician

Adequate

Spain

Population Based/General Population

ADOS, VABS

Multiple Clinicians

Excellent

2013

USA

Population Based/General Population

ADOS, ADI-R, VABS,
CARS

Single Clinician

Adequate

Coelho-Medeiros et al. (2019)

2019

Chile

High-Risk

ADOS

Unsure - Unclearly
Reported

Poor

Cuesta-Gomez et al. (2016)

2016

Argentina

Population Based/General Population

None

Unsure - Unclearly
Reported

Unacceptable

Guthrie et al. (2019)

2019

USA

Population Based/General Population

Unclear

Single Clinician

Adequate

Hoang et al. (2019)

2019

Vietnam

Population Based/General Population

None

Multiple Clinicians

Good

Kamio et al. (2014)

2014

Japan

Population Based/General Population

ADOS, ADI-R, CARS

Multiple Clinicians

Excellent

Study

Year

Country

Study Type

Baduel et al. (2017)

2017

France

Canal-Bedia et al. (2011)

2011

Chlebowski et al. (2013)

Clinical Description

Flagged by
pediatricians
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Table 1 (Continued)

Diagnostic Measure

Diagnosis

Rank Based on
Figure 4

Population Based/General Population

None

Unsure - Unclearly
Reported

Unacceptable

Turkey

Population Based/General Population

CARS

Single Clinician

Adequate

2018

Spain

Population Based/General Population

ADOS, VABS

Single Clinician

Adequate

Matson et al. (2013)

2013

USA

High-Risk

None

Single Clinician

Adequate

Nygren et al. (2012)

2012

Sweden

Population Based/General Population

ADOS, VABS

Multiple Clinicians

Excellent

Oien et al. (2018)

2018

Norway

Population Based/General Population

ADOS, ADI-R

Unsure - Unclearly
Reported

Poor

Oner & Munir (2019)

2019

Turkey

Population Based/General Population

ADOS

Single Clinician

Adequate

Snow & Lecavalier (2008)

2008

USA

High-Risk

ADOS, ADI-R

Multiple Clinicians

Excellent

Study

Year

Country

Study Type

Kerub et. al. (2018)

2018

Israel

Kondolot et. al. (2016)

2016

Magan-Maganto et. al. (2018)

Clinical Description

Early intervention
system

Specialty clinic
referrals
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Table 1 (Continued)

Study

Year

Country

Study Type

Clinical Description

Diagnostic Measure

Diagnosis

Rank Based on
Figure 4

Srisinghasongkram et al. (2016)

2016

Thailand

High-Risk

Identified with
language delay

None

Multiple Clinicians

Good

Sturner et al. (2013)

2013

USA

High-Risk

Testing at an
Autism Center

ADOS

Single Clinician

Adequate

Toh et al. (2018)

2018

Malaysia

Population Based/General Population

None

Single Clinician

Adequate

High-Risk

Social Pediatrics
Department Ankara
University

None

Single Clinician

Adequate

High-Risk

Referred from Child
Development
Clinics

None

Multiple Clinicians

Good

High-Risk

Suspected
developmental
delays from home
visits

ADOS

Single Clinician

Adequate

Topcu et al. (2018)

Tsai et al. (2019)

Wong et al. (2018)

2018

2019

2018

Turkey

Taiwan

Taiwan

Figure 5 was created with QUADAS-2 bias assessments for each study’s methodological
quality. The “Flow and Timing” stands out as the category with a large majority (18/22, 81.8%)
of studies with high bias for these studies with reference standard the second highest bias group
with 10/22 (45.5%). The other two QUADAS-2 domains provide a large majority of studies
matching low bias criteria for qualitative assessments. This qualitative assessment means that up
to a quarter of studies are questionable for inclusion in the quantitative analysis.
Figure 5
QUADAS-2 Results

Diagnostic Accuracy of Screening Tools
The accuracy of screening tools was evaluated in 22 peer reviewed publications reporting data on
24 independent samples utilizing the M-CHAT for screening population based or high-risk
samples. The full collected study metrics are shown in Table 2 below. As described in Table 3
the pooled sensitivity was 0.782 (95% CI 0.663-0.867) and the pooled specificity was 0.980
(95% CI 0.941-0.988). The LR+ was 41.826 (95% CI) and the DOR was 192.100 (95% CI
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76.267 – 483.858).. The reported Se of each study varied between 0.18 and 1.00 and the Sp
varied between 0.38 and 1.00.
Table 2
Reported Study Accuracy Metrics as Reported by Collected Studies

Study

Year

TP

TN

FP

FN

Sensitivity

Specificity

PPV

NPV

LR+

Baduel et al. (2017)

2017

12

1201

8

6

0.67

0.99

0.60

1.00

100.75

Canal-Bedia et al.
(2011)

2011

6

2024

25

0

1.00

0.99

0.19

1.00

81.96

Canal-Bedia et al.
(2011)

2011

23

2394

63

0

1.00

0.97

0.27

1.00

39.00

Chlebowski et al.
(2013)

2013

92

18269

79

6

0.94

1.00

0.34

1.00

218.03

Coelho-Medeiros et
al. (2019)

2019

1

90

1

0

1.00

0.83

Coelho-Medeiros et
al. (2019)

2019

17

0

3

0

1.00

0.83

Cuesta-gomez et al.
(2016)

2016

1

402

1

0

Hoang et al. (2019)

2019

129

17021

118

1

0.99

0.99

0.51

1.00

144.13

Kamio et al. (2014)

2014

20

1683

24

22

0.48

0.99

0.45

11.00

33.43

Kerub et al. (2018)

2018

7

1538

43

3

0.70

0.98

0.20

1.00

Kondolot et al. (2016)

2016

2

2004

15

0

1.00

0.99

0.12

1.00

134.60

Magan-Maganto et al.
(2018)

2018

9

3485

10

2

0.82

1.00

0.08

1.02

285.95

Matson, et al. (2013)

2013

150

151

150

101

0.60

0.50

1.20
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Table 2 (Continued)
Study

Year

TP

TN

FP

FN

Sensitivity

Specificity

PPV

NPV

Oien et al. (2018)

2018

69

67969

1402

228

Oner & Munir (2019)

2019

57

6388

95

Snow & Lecavalier
(2008)

2008

38

5

Srisinghasongkram et
al. (2016)

2016
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Sturner et al. (2013)

2013

Topcu et al. (2018)

0

1.00

0.91

0.09

1.00

8

5

0.88

0.38

0.83

0.50

1.44

785

2

5

0.91

1.00

0.96

0.99

357.06

23

4568

17

16

0.59

1.00

0.38

6.22

159.06

2018

3

465

15

0

1.00

0.92

0.07

1.00

Tsai et al. (2019)

2019

19

273

17

3

0.88

0.94

0.61

0.99

Wong et al. (2018)

2018

65

115

58

14

0.46

0.93

Oien et al. (2018)

2018

69

67969

1402

228

Oner & Munir (2019)

2019

57

6388

95

0

1.00

0.91

0.09

1.00

Snow & Lecavalier
(2008)

2008

38

5

8

5

0.88

0.38

0.83

0.50

1.92

The reported TP, TN, FP, and FN of table 2 were used to calculate sensitivity, Sp, and
DOR for all studies which can be seen in Figures 6,7, and 8. The forest plots in Figure 6 show
substantial variability in sensitivity with a minimum point estimate of 0.23 and a maximum of
0.99. For Sp many studies show highly specific estimate with fewer exhibiting large confidence
intervals, the min. was 0.39 and max. was 0.99.

LR+

1.44

Figure 6
Sensitivities of Included Studies Organized by Population Based or High-Risk
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Figure 7
Specificities of Included Studies Organized by Population Based or High-Risk
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Figure 8
Natural LOG DOR of Included Studies Organized by Population Based or High-Risk

Table 3
Meta-Analysis Estimates All Studies
Point Estimate

95% Lower Bound

95% Upper Bound

DOR

192.100

76.267

483.585

Pooled Sensitivity

0.782

0.663

0.867

Pooled Specificity

0.980

0.954

0.991

Exploration of Heterogeneity
Using the Cochran Q test, the DOR of 24 data sets were assessed for heterogeneity and
the results were found to be 28.47 (df = 23, p = 0.198) which shows there is insubstantial
heterogeneity in the sample. However, Study Type level analyses were planned a priori and thus
conducted. In addition to the Cochran Q test, the spearman rho correlation between sensitivity
and false positive rate (FPR) is 0.184 (-0.237, 0.547). This suggests there are no threshold effects
between sensitivity and FPR in this analysis (though, as previously mentioned, there is low
power).
Using all 24 sets of data an SROC curve was constructed displaying sensitivity and FPR.
The studies were similar in that all M-CHAT scoring was based on suggested original cut-off
values proposed by Robins (2001, 2014) except one study, Kamio et al. (2014). A variation
between the studies collected was whether or not they used solely the M-CHAT’s initial stage,
the follow-up stage or a combination of the two. The prediction region shows a wide range for
both FPR and sensitivity when considering all studies. Figure 9 demonstrates that studies vary in
their results even though they all report on M-CHAT screening. Figure 10 shows the entire
sample of studies sensitivity related to the FPR visualized as an SROC. The 95% interval is
situated above 0.6 sensitivity and less than 0.1 FPR. There are four notable studies with low
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FPR; it is noteworthy is that all four are high-risk studies (Coelho-Modeiros et al., 2019; Matson
et al., 2013; Snow & Lecavlier, 2008; Wong et al., 2018).
Figure 9
ROC Ellipse and Confidence Intervals of all Studies
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Figure 10
Bivariate Reitsma SROC of All Included Studies

Subgroup Comparisons
Population vs. Clinical Study Types
Even though the data was not found to be heterogeneous based on the Cochrane Q test,
subgroup comparisons were performed between the studies examining general populations and
those examining clinical populations. When examining Figures 6, 7, and 8 again the studies are
organized first by Study Type, population based first and then high-risk, in order to visually
describe similarities by Study Type. The clinical studies display substantially lower and different
sensitivity and specificity than population based studies this is shown in Figure 6 and 7.
The forest plot of Figure 6 shows variability in the sensitivity of the studies as a whole,
but assessing the sensitivity by population based or high-risk reduces the variation and partially
explains some Study Type relationship. A similar visual description is seen in Figure 7 where
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variability is largely contained by the high-risk studies, and Figure 8, where the DOR is high and
significant for all population based studies but some high-risk show non-significant results. The
population specificities have a tight range from 0.92 to 1.00 while the clinical has a much wider
range of estimates. Splitting these by their subgroups has helped to clarify the differences
between these two study types when describing their sensitivity and specificity. Examining the
high-risk studies once again, in Figure 8, shows more variability where one study, Matson
(2013), had a DOR of less than 1.0 with a confidence interval that did not cross 1.0 indicating a
significant result.
When inspecting the numbers closer, Table 4 serves to show the specifics of the
univariate characteristics of data sets when they are split. The summary estimates that are used in
Figures 6, 7, and 8 are shown here more clearly with their confidence intervals (95% CI). For
population based studies the pooled sensitivity was 0.746 (0.555, 0.874) and the pooled Sp was
0.992 (0.985, 0.995). The estimate of sensitivity for the high-risk study types (0.821 (0.701, 0.900)
is higher than the population based counterpart, but has a lower estimate for specificity 0.906
(0.639, 0.981). The difference in DOR between the two is large as well with a population DOR of
396.756 (126.753, 1241.906) and high-risk of 58.389 (8.318, 409.866). Like with the full sample
Cochran Q and Spearmans’s rho is non-significant for each of these study samples.
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Table 4
Univariate Statistical Measures of Included Studies by Study Type
Population

df

p-value

Clinical

df

p-value

k

15

9

Equality of

364.986

14

<0.001

56.8563

8

<0.001

4586.487

14

<0.001

2621.484

8

<0.001

Sensitivities
Equality of
Specificities
Rho (95% CI)

-0.388 (-0.725, 0.211)

0.114 (-0.595, 0.723)

DOR (95% CI) 396.756 (126.753,

58.389 (8.318, 409.866)

1241.906)
Cochran’s Q

13.488

Tau of DOR

2.055 (0.000, 2.551)

2.811 (0.000, 4.388)

4.221 (0.000, 6.508)

7.901 (0.000, 19.258)

0.746 (0.555, 0.874)

0.821 (0.701, 0.900)

0.992 (0.985, 0.995)

0.906 (0.639, 0.981)

14

0.489

6.95

14 0.542

(95% CI)
Tau2 of DOR
(95% CI)
Sensitivity
(95% CI)
Specificity
(95% CI)

The following tables represent the meta-regression analysis. Table 5 reports the log
likelihood of each model and the comparison to the null model. The log likelihood of the model
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incorporating Study Type (population based and high-risk) is 64.075. The Chi-squared analysis
of the model is significant at p = 0.004 showing that Study Type model explains some of the
heterogeneity between included studies. Finally Table 6 shows the meta regression table for
Study Type. For the Study Type model the regression coefficient for the FPR is significant,
indicating that the population based studies result in a better FPR than high-risk studies.

Table 5
Regression Model Performance Comparison Characteristics
Study Type
Model
Log Likelihood
64.075
df
7
k
2
AIC
-114.149
BIC
-101.051
CHI-SQ (df, p-value)
10.84 (2, 0.004*)
Note. Significant p-value set at α=0.10

Null Model
57.850
5
2
-105.699
-96.343

Table 6
Bivariate Meta-Regression Coefficients
Estimate
2.5% CI
97.5% CI
Study Type Model
Sensitivity (Intercept)
1.673
0.712
2.634
Sensitivity Population Based -0.647
-1.871
0.577
FPR (Intercept)
-2.343
-3.508
-1.179
FPR Population Based
-2.443
-3.904
-0.982
Note. The control group for the Study Type model is High-Risk samples.

Multi-Clinician vs Other Reference Standard

p-value
0.001*
0.300
0.000*
0.001*
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Figures 11, 12, and 13 show the sensitivity, specificity, and DOR with summary
estimates when organized by reference standard level. These forest plots are very similar to
Figures 6, 7, and 8 for use describing the breakdown of these two groups visually. When
observing these studies organized by Multi-Clinician and Other there appears to be variability in
both levels of reference standard quality. Sensitivity shows high variability throughout the
studies in Figure 11 while Specificity shows less variability overall in Figure 12. Unlike the
Study Type breakdown, where most variability was seen in the high-risk studies, the variability
of Reference Standard does not appear to be represented by one level more than the other. Using
Table 7 The pooled sensitivity estimate of Multi-Clinician reference standard in 0.874 and the
pooled estimate of Other is 0.711. The CI regions of these estimates overlap but the point
estimate difference is 0.163 for sensitivity. The specificities on the other hand are very similar,
0.983 and 0.978 for Multi-Clinician and Other respectively. Finally, the DORs are 460.927 and
121.330 for Multi-Clinician and Other respectively show a large difference between the two
point estimates and a much higher DOR for Multi-Clinician.
Descriptive characteristics of these groupings of data are the Cochran Q test and Spearman’s
Rho. The Cochran’s Q shows a non-significant result indicating no heterogeneity within the
groupings of excellent and good or the grouping of adequate, poor, and unacceptable.
Spearman’s rho for these sets of data are 0.102 (-0.649, 0.753) and 0.247 (-0.283, 0.662) both
non-significant results and indicating no threshold effects between sensitivity and FPR in either
of these sets of data. These results can be seen in Table 4.

Figure 11
Sensitivities of Included Studies Organized by Multi-Clinician or Other Reference Standard
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Figure 12
Specificities of Included Studies Organized by Multi-Clinician or Other Reference Standard

Figure 13
Natural LOG DOR of Included Studies Organized by Multi-Clinician or Other Reference Standard

Table 7 shows the univariate characteristics of data sets when they are split by Reference
Standard level. The summary estimates that are used in Figures 11, 12, and 13 are shown here
more clearly with their confidence intervals. For Multi-Clinician studies the pooled sensitivity
was 0.874 (0.711, 0.951) and the pooled Sp was 0.983 (0.927, 0.996) which is higher than the
estimate of sensitivity and specificity for the Other reference standard study types, 0.711 (0.552,
0.831) and 0.978 (0.939, 0.992). The difference in DOR between the two is large as well with a

Multi-Clinician DOR of 460.927 (73.658, 2884.340) and Other DOR of 121.330 (42.312, 347.913).
Finally, Cochran’s Q and Spearman’s rho are non-significant for both of these sets of studies.

Table 7
Univariate Statistical Measures of Included Studies by Reference Standard
Multi-Clinician
k

8

Equality of Sensitivities

83.797

Equality of Specificities 748.783

df

p-value

Other

df

p-value

16
7

<0.001

291.9054

15

<0.001

7

<0.001

7423.318

15

<0.001

15

0.162

Rho (95% CI)

0.102 (-0.649, 0.753)

0.247 (-0.283, 0.662)

DOR (95% CI)
Cochran’s Q

460.927 (73.658,
2884.340)
7.008

121.330 (42.312,
347.913)
20.253

Tau (95% CI)

2.491 (0.000, 4.617)

1.929 (0.000, 3147)

Tau2 (95% CI)

6.204 (0.000, 21.314)

3.720 (0.000, 9.902)

Sensitivity (95% CI)

0.874 (0.711, 0.951)

0.711 (0.552, 0.831)

Specificity (95% CI)

0.983 (0.927, 0.996)

0.978 (0.939, 0.992)

7

0.428
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Table 8 shows the comparison of the Reference Standard model to the null model. The
CHI-SQ analysis is not significant for this model, (p = 0.240). This model regressed on
Reference Standard does not substantially explain the heterogeneity of these studies more than
the null model. Table 9 shows the results of the meta-regression as a regression table for
Reference Standard model. For the Reference Standard model neither regression coefficient is
significant indicating neither reference standard ranking of Multi-Clinician or Other offers
significantly better sensitivity or FPR. However, these findings should be judged in light of the
low power of the study and that we considered p < .10 to indicate potentially meaningful
relationships; the Reference Standard analysis indicates a trend may be present wherein studies
with Multi-Clinician reference standards have higher sensitivities than those without.
Table 8
Regression Model Performance Comparison Characteristics

Log Likelihood
df
k
AIC
BIC
CHI-SQ (df, p-value)

Reference Standard
Model
Null Model
60.466
57.850
7
5
2
2
-106.932
-105.699
-93.833
-96.343
2.855 (2, 0.240)

Table 9
Bivariate Meta-Regression Coefficients
Estimate
2.5% CI
97.5% CI
p-value
Reference Standard Model
Sensitivity (Intercept)
1.913
0.930
2.897
0.000*
Sensitivity Other
-0.999
-2.213
0.214
0.107
FPR (Intercept)
-4.034
-5.523
-2.545
0.000*
FPR Other
0.243
-1.585
2.071
0.794
Note. The control group for the Reference Standard Model is Multi-Clinician reference standard.

Diagnostic accuracy metrics differ between population and clinical studies as illustrated by

Table 4 and in the bivariate Reitsma illustrated in Figure 14. The population based and high-risk
study samples can further be broken up by reference standard quality categories. This further
analysis can be observed in Appendix D where Supplemental Figure 1 and 2 show SROC plots
of population based and high-risk studies by reference standard criteria. When assessing the
population-based studies by sensitivity and FPR (1-specificity), they are all grouped near 0 FPR,
but widely variable when assessed by sensitivity. The high-risk studies are variable in both
sensitivity and false positive rate indicating these types of studies may vary on more between
them in terms of study variance.
Figure 14
Comparison of Bivariate Reitsma models for Population Based and High-Risk Studies Through
SROC

Finally, the last subgroup comparison, Reference Standard, is shown in Figure 15 where
the studies have been split into groups based on their strength of reference standard. While the
proposed framework of ranking screening accuracy studies has 6 levels, the studies of this
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systematic review only identified reference 5 levels of reference standard: Excellent, Good,
Adequate, Poor and Unclear. These were split into Multi-Clinician and Other categories. The
SROC ellipse shows Multi-Clinician and Other overlap however the Multi-Clinician group
appears to be better than the Other category.
Figure 15
Comparison of Bivariate Reitsma models for Multi-Clinician and Other Reference Standard
Levels Through SROC
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Discussion
This study identified 24 samples across 22 peer-reviewed publications reporting data on
TP, TN, FP, and FN from which we conducted a MADA. The combined accuracy was
summarized by the bivariate Reitsma model. The results of the full combined study sample
analysis shows a summary estimate of 192.100 (95% CI 76.267, 483.858) indicating that the
odds of a positive result on the M-CHAT is 192 times more likely on a patient with ASD than on
a patient without ASD. Other than DOR the LR+ was 37.368 indicating positive cases were
likely to be indicated by a positive test result and the LR- was 0.337 indicating that positive cases
were not likely to be indicated by a negative test result. Despite the fact that our heterogeneity
scores did not indicate any significant between-study heterogeneity, the decision was made a
priori to split the studies by the level at which their populations were collected, population-based
vs high-risk. This knowledge was informed by Tipton et al. (2019) who recommend best practice
of reducing confounding by separating moderators which may have an association with one
another; in this case study level of population based and high-risk samples. The meta-regression
showed that population-based samples have significantly lower FPR than high-risk studies. More
generally, when compared to clinical studies, population-based studies appear to show much
higher DOR, 396.756 (126.753, 1241.906) than high-risk studies, 58.389 (8.318, 409.866) and
pooled specificity, 0.992 (0.985, 0.995) to 0.906 (0.639, 0.981) but a lower pooled sensitivity
0.746 (0.555, 0.874) than the high-risk studies 0.821 (0.701, 0.900).
While population based vs high-risk was an expected sample difference, the main focus
of this study was clinical reference standard. We conducted an additional meta-regression of
reference standard showing that while we hypothesized an inverse relationship between
reference standard, this was not fully explored due to the low power of this universe. Instead, we
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conducted a meta-regression between Multi-Clinician reference standards and Other which
yielded interesting data. The Multi-Clinician reference standard showed a higher DOR 460.927
(73.658, 2884.340), sensitivity 0.874 (0.711, 0.951), and specificity 0.983 (0.927, 0.996) than the

Other group’s results of 121.330 (42.312, 347.913), 0.711 (0.552, 0.831), 0.978 (0.939, 0.992),
respectively. The DOR and sensitivity differences appear to be large, however the specificity
differences are quite small. This binary split shows a positive relationship between multi-clinician
outcomes and reference standard quality, however this result was not significant when performing a
meta-regression. Ideally the number of studies included would give sufficient power to every

reference standard category. This study has too few studies per group and so a grouping
technique, Mutli-Clincian and Other, was employed to increase the size of the categories.Even
when employing this technique the power remains low. Collectively, these results indicate that
there is not a significant difference between Multi-Clinician reference standard and Other when
determining sensitivity and FPR, though meta-regression suggested a trend.
A secondary analysis was attempted when studies were split by Study Type. These results
are displayed in Appendix D. A meta-regression was not performed on this data, due to low
power. If this work is analyzed only visually, the relationships apparent show a small difference
in the sensitivity between population based samples who employ Multi-Clinician reference
standards over Other but not much difference in FPR. For High-Risk samples the sensitivity once
again is favored by Multi-Clinician, however FPR is significantly different between these two.
The high-risk sample included 9 studies total which may bias these results. The conclusion
reached from this analysis is that these results can be viewed as preliminary. The relationship
between Reference Standard within population based or high-risk studies should be pursued by a
systematic review and meta-analysis with more inclusion criteria, possibly through including the
grey literature.
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This study is unique in the universe of screener reviews in a number of different ways.
First, this study includes both a study that Sanchez-Garcia missed, Magan-Maganto and a sample
that Yuen missed. Yeun also notes Stenberg et al. (2014), but our study includes this sample in
Oien et al. (2018). Furthermore, of the existing quantitative reviews none explore the effect of
high-risk vs population studies or reference standard effects on diagnostic outcomes. Despite its
non-significance, this analysis helps underscore that studies utilizing different reference
standards might impact diagnostic outcomes, and should be considered for other MADA studies.
The particular focus on the M-CHAT is important as recent research from Guthrie et al.
(2019) indicates that the current published screener studies have identified too few cases and
long term follow-up shows the M-CHAT has a lower rate of accuracy than initially thought.
Specifically, their calculated sensitivity was 0.388 and specificity was 0.949, which is
substantively lower than sensitivity of .911 and specificity of .955 as reported by Robins et al.
(2014). A preliminary exploratory analysis in Appendix E showed that using a population
prevalence baseline estimate to adjust FN and TN metrics can mimic the effect of complete
follow-up. Supplemental Table 1 shows the original reported study values, population prevalence
estimate matched by country and year and adjusted study metrics. Supplemental Figure 3, 4, and
5 show sensitivity, specificity, and DOR that can be compared to original forest plots in figure 6,
7, and 8 in the population based study section. This strategy was an idea taken from Barbaro et
al. (2010) who used Australian prevalence estimate rates for ASD instead of following-up all
negatives. After using their idea of population prevalence baseline, our largest study,
Chlebowski, had adjusted sensitivity of 0.34 which closely resembles the follow-up adjusted
metrics of the Guthrie study. More information on the preliminary exploratory analysis can be
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observed in Appendix E. Guthrie leaves readers with the task of identifying new methods to
detect a greater proportion of children with ASD.
The studies included in this review were selected because the authors reported all TP,
TN, FN, and FP data points. The main focus was to use clear psychometric data to calculate
MADA while fitting the analysis into the timeline of a thesis. While these studies served their
purpose of psychometric data reporting, some studies were found to lack positive qualities from
an ASD identification process focus, based on Figure 1. Certain studies were noted during the
QUADAS-2 process for not even including a flow chart, specifically Matson et al. (2013), Oien
et al. (2018), Snow& Lecavalier (2008), and Toh et al. (2018) making it difficult to ensure
numbers reported could be correctly replicated or when trying to understand the flow of their
studies visually. QUADAS-2 drastically helped to pinpoint which domains this literature base
needed improvement on; specifically Domain 4: “Flow and Timing” needed improvement
because many studies resulted in high bias estimates (18/22, 81.8%) due to the amount of
questions that had to be marked “unclear”. The QUADAS-2 covers all categories that need to be
reviewed for collecting and reviewing studies for a meta-analysis. Besides Flow and Timing,
results for the Domains: 1 Patient Selection and 2 Index Test were generally low bias while
Domain 3: Reference Standard has a large number of unclear results as marked by this study.
The QUADAS-2 review likely found more unclear results due to the ranking system modeled
previously by Barger and redesigned for this study. Because of the strict guidelines of
information to collection our focus on reference standard categories resulted in numerous high
bias estimates as opposed to similar reviews that did not use strict methods.
This study highlights a main area where research on the early identification process can
improve: Clarity of reference standard reporting in all literature, particularly peer-reviewed
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publications. Screening tools are an important aspect of early identification, but are most useful
when predicting in a system with high quality diagnosis and long term ability to continue
monitoring potential cases (Barger et al., 2018). Improvements to reference standard reporting in
peer-reviewed articles can be seen in this study’s diagnostic framework which extends the
QUADAS-2 by improving the categorical analysis in Domain 3: Reference Standard. This is
done by creating specific and reproducible levels for bias estimates instead of general “low” or
“high” bias labels. Thus, this framework might be useful for future meta-analysis studies or for
the QUADAS-2 Appendix F to guide new bias categories this may reduce the amount of
“unclear” answers for studies when performing a QUADAS-2 review for Domain 3.
Systematic reviews and meta-analyses have tremendously helpful guidelines to follow (Pigott &
Polanin, 2020; Polanin et al., 2019). The guidelines help keep the focus on the review question
and therefore more able to answer the question. This study adds to systematic review methods by
creating robust and defendable clinical reference standard categories that accounts for important
insights about reference standard norms from the field of autism research. There may be more
room for improvement since the original categories had to be modified to fit the data of this
study, but disambiguating single clinician diagnosis from multi-clinician diagnosis is a valid
change to the original format. Future direction should seek to use frameworks, such as seen in
Figure 4 Redesigned Framework for Categorical Assessment of Reference Standards. It’s
important for Categorical analysis that the meaning of a category is well defined which is not the
case with QUADAS-2 Domain 3: Reference Standard questions. A more focused reference
standard review can lead to better comparison of MADA results from other studies by
accounting for reference standard quality in the study collection phase.
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Limitations
This study required a number of important methodological decisions, each with a
potential limitation. First, M-CHAT studies vary in their choice cut-off rules and following up
with positive and negative screens, and within text descriptions are often opaque. When
available, we prioritized using flow charts to best determine identification procedures and
interpret in-text descriptions; however, alternative approaches could be developed. In this review
there are two studies that report two sample sets, Canal-Bedia et al. (2011) and Coelho-Medeiros
et. al. (2019), because within-publication samples were collected independent of one another
they are both reported and not expected to compromise findings. One major advantage of this
work is that all studies used recommended M-CHAT cut-off scores (except Kamio) which likely
helped control for a source of heterogeneity (Doebler & Bohning, 2010). The implications of
including only studies that report all of their own metrics are that they can be misleading.
Sensitivity and specificity from partial data across more studies can be back calculated which
was not performed by this study to confirm the reported psychometric data reported. This would
fill gaps in the current literature because this level of confirmation is not present in current
MADA studies.
The second important limitation is related to the number of primary studies that do not
follow up all negative screens in order to determine the absolute number of false negatives that
exist in their sample. In addition to not following up all negative screens, not all studies report
sample demographics which may explain screening differences because individuals of different
races have been shown to screen differently with the M-CHAT (Khowaja et al., 2015). This is an
important methodological choice for study inclusion because this will positively bias
psychometric results due to the likely under-identified number of cases reported in any given
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study that does not follow-up completely. During the meta-regression there is indication that
population based studies have significantly higher FPR which would the factor most affected by
not following up on a sample for TN.
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Appendix A
Cross table and list of presumed outliers in the
data

TP/TN outlier: Matson (150, 151) Hoang (129, 17021) Chlebowski (92, 18269) Oien (69, 67969)
TP/FP outlier: Matson (150, 150) Hoang (129, 118) Chlebowski (92, 79) Oien (69, 1402)
TP/FN outlier: Matson (150, 101) Hoang (129, 1) Chlebowski (92, 6) Oien (69, 228)
TN/FP outlier: Oien (67969, 1402)
TN/FN outlier: Oien (67969, 228) Matson (150, 101)
FP/FN outlier: Oien (1402, 228) Matson (150, 101)
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Appendix B
Modified-Checklist for Autism in Toddlers

M-CHAT
Please fill out the following about how your child usually is. Please try to
answer every question. If the behavior is rare (e.g., you've seen it once or
twice), please answer as if the child does not do it.
1.Does your child enjoy being swung, bounced on your knee, etc.? Yes No
2.Does your child take an interest in other children? Yes No
3.Does your child like climbing on things, such as up stairs? Yes No
4.Does your child enjoy playing peek-a-boo/hide-and-seek? Yes No
5.Does your child ever pretend, for example, to talk on the phone or take care
of a doll or pretend other things? Yes No
6.Does your child ever use his/her index finger to point, to ask for
something? Yes No
7.Does your child ever use his/her index finger to point, to indicate interest in
something? Yes No
8.Can your child play properly with small toys (e.g. cars or blocks) without
just mouthing, fiddling, or dropping them? Yes No
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9.Does your child ever bring objects over to you (parent) to show you
something? Yes No
10.Does your child look you in the eye for more than a second or two? Yes
No
11.Does your child ever seem oversensitive to noise? (e.g., plugging ears)
Yes No
12.Does your child smile in response to your face or your smile? Yes No
13.Does your child imitate you? (e.g., you make a face-will your child imitate
it?) Yes No
14.Does your child respond to his/her name when you call? Yes No
15.If you point at a toy across the room, does your child look at it? Yes No
16.Does your child walk? Yes No
17.Does your child look at things you are looking at? Yes No
18.Does your child make unusual finger movements near his/her face? Yes
No
19.Does your child try to attract your attention to his/her own activity? Yes
No
20.Have you ever wondered if your child is deaf? Yes No
21.Does your child understand what people say? Yes No
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22.Does your child sometimes stare at nothing or wander with no purpose?
Yes No
23.Does your child look at your face to check your reaction when faced with
something unfamiliar? Yes No
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Appendix C
QUADAS-2 Appendix F Questions
Domain 1: Patient selection
A. Risk of bias
Describe methods of patient selection:
.
.
.
.
Was a consecutive or random sample of patients enrolled?

Yes / No / Unclear

Was a case-control design avoided?

Yes / No / Unclear

Did the study avoid inappropriate exclusions?

Yes / No / Unclear

Could the selection of patients have introduced bias?
Risk: Low / High / Unclear
B. Concerns regarding applicability
Describe included patients (prior testing, presentation, intended use of index test and setting):
.
.
.
Is there concern that the included patients do not match the review question?
Concern: Low / High / Unclear
Domain 2: Index test(s)
A. Risk of bias
Describe the index test and how it was conducted and interpreted:
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.
.
.
.
Were the index test results interpreted without knowledge of the results of Yes / No /
the reference standard?
Unclear
If a threshold was used, was it pre-specified?

Yes / No /
Unclear

Could the conduct or interpretation of the index test have introduced bias?
Risk: Low / High / Unclear
B. Concerns regarding applicability
Is there concern that the index test, its conduct, or interpretation differ from the review
question?
Concern: Low / High / Unclear
Domain 3: Reference standard
A. Risk of bias
Describe the reference standard and how it was conducted and interpreted:
.
.
.
.
Is the reference standard likely to correctly classify the target condition?

Yes / No /
Unclear

Were the reference standard results interpreted without knowledge of the
results of the index test?

Yes / No /
Unclear

Could the reference standard, its conduct, or its interpretation have introduced bias?
Risk: Low / High / Unclear
B. Concerns regarding applicability
Is there concern that the target condition as defined by the reference standard does not
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match the review question?
Concern: Low / High / Unclear
Domain 4: Flow and timing
A. Risk of bias
Describe any patients who did not receive the index test(s) and/or reference standard or who
were excluded from the 2x2 table (refer to flow diagram):
.
.
.
Describe the time interval and any interventions between index test(s) and reference standard:
.
.
.
.
Was there an appropriate interval between index test(s) and reference
standard?

Yes / No / Unclear

Did all patients receive a reference standard?

Yes / No / Unclear

Did patients receive the same reference standard?

Yes / No / Unclear

Were all patients included in the analysis?

Yes / No / Unclear

Could the patient flow have introduced bias?
Risk: Low / High / Unclear
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Appendix D
Population based and high-risk studies broken into reference standard categories
Supplemental Figures 1 and 2 are the bivariate Reitsma illustrated by an SROC of
subgroup analysis and clinical reference criteria. In Figure 17 Multi-Clinician reference standard
shows a higher sensitivity than Other and neither are significantly different in FPR. In Figure 18
Multi-Clinician reference standard has a higher sensitivity but Other appears to have a
significantly better FPR.

Supplemental Figure 1
SROC of Population by Reference Standard
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Supplemental Figure 2
SROC of Clinical by Reference Standard
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Appendix E
Exploratory Analysis of Population Based Estimate
In figure 17 the original sensitivity metrics are compared to the adjusted sensitivity metrics.
Between these two forest plots there are six studies whose metrics were adjusted: Chlebowski,
Hoang, Kondolot, Oien, Oner, and Toh. Due to the nature of the adjustments all of these resulted
in the sensitivity estimate being lowered, some of these were lowered significantly like
Chlebowski from 0.93 to 0.34. Figure 22, shows similar changes but with specificity, these
comparisons are interesting because the six studies where adjustments are made, no point
estimates changed from the original study to the adjusted version. Figure 17, resembles more of
figure 21, where the 6 studies whose metrics were adjusted changed. None were reduced to the
point of being non-significant. The adjusted Se became 0.522 from the original of 0.746 and the
adjusted Sp did not change from the original of 0.992.

Supplemental Table 1
Adjusted identification metrics of population-based studies
Pop.
Author

Country

Size

TP

FN

FP

TN

Identified

Prev. Est.

Prev. Est.

year

Author

Baduel et al.
(2017)

ADJ

ADJ

Prev. Est.

Expected

Difference

ADJ FN

Change

TN

Sensitivity

Specificity

0.00365

5

-13

6

No

1201

0.6667

0.993383

0.001297

3

-20

0

No

2024

1.00

0.987799

0.014493

275

104

183

Yes

18165

0.3343

0.99567

0.01

1

-16

0

No

90

1.00

0.989011

0.00131

1

0

0

No

402

1.00

0.997519

0.016949

345

-109

249

No

18263

0.4515

0.916771

0.01

178

48

49

Yes

16973

0.7266

0.993096

0.01811

34

-8

22

No

1661

0.4762

0.985757

0.001

2

-8

3

No

1538

0.700

0.972802

Van Bakel et
France

1250

12

6

8

1201

18

2015

Canal-Bedia et al.
(2011)

ADJ

al. (2017)

Adak &
Spain

2055

23

0

25

2024

23

2007

Halder (2017)

Chlebowski,
Robins, Barton, &
Fein (2013)

1826

Baio et al.

USA

18989

92

79

79

9

171

2012

Chile

100

1

90

1

0

17

2013

Coelho-Medeiros
et al. (2019)

(2018)

Van Cong et
al. (2015)

Cuesta-gomez,
Manzone, PosadaDe-La-Paz (2016)

Elsabbagh et
Argentina

420

1

0

1

Guthrie et al.
(2019)

1

2008

1826
USA

20375

205

249

1658

Hoang et al.
(2019)

402

3

Baio et al.
454

2014

1702
Vietnam

17754

129

1

118

1

al. (2012)

(2018)

Van Cong et
130

2013

al. (2015)

Kawamura et
Kamio et al (2014)

Japan

1851

20

22

24

1661

42

2008

Kerub et al (2018)

Isreal

1591

7

3

43

1538

10

2001

al. (2008)

Davidovitch
et al. ((2013)
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Pop.
Author

Country

Size

TP

FN

FP

TN

Identified

Prev. Est.

Prev. Est.

year

Author

Kondolot et al
2016

ADJ

ADJ

Prev. Est.

Expected

Difference

ADJ FN

Change

TN

Sensitivity

Specificity

0.01

20

18

18

Yes

1986

0.0989

0.992503

0.001297

5

-6

2

No

3485

0.8182

0.997139

0.0062

25

-23

15

No

3939

0.6875

0.999239

0.0087

606

309

537

Yes

67660

0.1138

0.979699

0.01

65

8

8

Yes

6380

0.8716

0.985327

0.01

163

113

145

Yes

16114

0..1105

0.99876

Van Cong et
Turkey

2021

2

0

15

2004

2

2013

Magan-Maganto
et al (2018)

ADJ

al. (2015)

Adak &
Spain

3529

9

2

10

3485

11

2007

Halder (2017)

Fernell &
Nygren et al

Gillberg

(2012)

Sweden

3985

33

15

3

Oien et al (2018)

Norway

69668

69

228

1402

3939

48

2010

297

2010

6796
9

Posserud et

Oner & Munir
(2019)

al. (2010)

Van Cong et
Turkey

6540

57

0

95

Malaysia

16297

18

32

20

Toh, Tan, Lau, &
Kiyu (2018)

(2010)

6388

57

2013

50

2013

1622
7

al. (2015)

Van Cong et
al. (2015)

Supplemental Figure 3
Adjusted Sensitivity Metrics of Population Based Studies by Population Prevalence Estimates
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Supplemental Figure 4
Adjusted Specificity Metrics of Population Based Studies by Population Prevalence Estimates
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Supplemental Figure 5
Adjusted DOR Metrics of Population Based Studies by Population Prevalence Estimates

